Urologix, Inc.
ULGX
$0.0001
$0.000.00%
| 03/31/2015 | 12/31/2014 | 09/30/2014 | 06/30/2014 | 03/31/2014 | |
|---|---|---|---|---|---|
| Revenue | -19.41% | -19.68% | -18.27% | -15.00% | -11.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.41% | -19.68% | -18.27% | -15.00% | -11.70% |
| Cost of Revenue | -24.51% | -7.45% | -3.84% | 0.07% | 1.07% |
| Gross Profit | -12.74% | -32.46% | -32.62% | -29.68% | -24.22% |
| SG&A Expenses | -43.44% | -40.52% | -32.74% | -20.21% | -10.81% |
| Depreciation & Amortization | -20.20% | -6.19% | -4.95% | -7.69% | -3.88% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.58% | -25.69% | -20.55% | -13.09% | -7.42% |
| Operating Income | 79.90% | 47.63% | 29.04% | 5.66% | -10.03% |
| Income Before Tax | 11.23% | -29.14% | -48.16% | -78.30% | -26.56% |
| Income Tax Expenses | -541.67% | -418.18% | -309.09% | -206.67% | -81.82% |
| Earnings from Continuing Operations | 12.42% | -28.09% | -47.30% | -77.30% | -24.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.42% | -28.09% | -47.30% | -77.30% | -24.88% |
| EBIT | 79.90% | 47.63% | 29.04% | 5.66% | -10.03% |
| EBITDA | 89.48% | 53.16% | 31.65% | 4.30% | -13.92% |
| EPS Basic | 13.48% | -26.05% | -44.58% | -72.74% | -9.46% |
| Normalized Basic EPS | 68.38% | 39.96% | 24.32% | 4.61% | -3.31% |
| EPS Diluted | 9.67% | -29.13% | -43.69% | -71.07% | -7.98% |
| Normalized Diluted EPS | 68.38% | 39.96% | 24.32% | 4.61% | -3.31% |
| Average Basic Shares Outstanding | 2.26% | 2.16% | 2.02% | 2.49% | 10.15% |
| Average Diluted Shares Outstanding | 2.26% | 2.16% | 2.02% | 2.49% | 10.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
